Research programme: multiple sclerosis therapeutics - Evotec AG

Drug Profile

Research programme: multiple sclerosis therapeutics - Evotec AG

Latest Information Update: 26 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Evotec AG
  • Developer Deutsches Rheuma-Forschungszentrum; Evotec AG; University Medical Center Hamburg-Eppendorf
  • Class
  • Mechanism of Action Cytokine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Multiple sclerosis

Most Recent Events

  • 24 Sep 2014 Evotec collaborates with the Deutsches Rheuma-Forschungszentrum and University Medical Center, Hamburg-Eppendorf, for three research projects supported by research funds from the German Federal Ministry of Education and Research
  • 24 Sep 2014 Early research in Multiple sclerosis in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top